Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Risk of Inflammatory Bowel Disease in Psoriasis Patients Treated with Anti-Interleukin-17 Agents: A Bayesian Metaanalysis

View ORCID ProfileN. Gill, M. Pietrosanu, View ORCID ProfileR. Gniadecki
doi: https://doi.org/10.1101/19012179
N. Gill
1Division of Dermatology, Faculty of Medicine, University of Alberta, Edmonton, AB, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for N. Gill
M. Pietrosanu
2Department of Mathematical & Statistical Sciences, Faculty of Science, University of Alberta, Edmonton, AB, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Gniadecki
1Division of Dermatology, Faculty of Medicine, University of Alberta, Edmonton, AB, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for R. Gniadecki
  • For correspondence: nkgill@ualberta.ca
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Use of interleukin-17 inhibitors (IL-17i) in psoriasis has been associated with an increased risk of inflammatory bowel disease (IBD). However, the clinical significance of this association is not understood.

Objectives To quantify the absolute risk of IBD in patients with psoriasis treated with IL-17i, stratified by known IBD risk factors.

Methods Literature searches were performed to identify known IBD risk factors and the prevalences were quantified by a meta-analysis of proportions. The Bayesian model was used to estimate the probability of a new-onset or a flare of IBD in patients with psoriasis.

Results The prevalence of Crohn’s disease (CD) or ulcerative colitis (UC) in the general psoriasis population was 0.0010. Use of IL-17i increased the risk of CD to 0.0037 and UC to 0.0028, translating to a number needed to harm (NNH) of 373 for CD and 564 for UC. In patients who had concomitant hidradenitis suppurativa, the use of IL-17i was associated with a decrease in NNH for CD and UC to 18 and 76, respectively, whereas for patients with a family history of IBD, the NNH values were 6 (for CD) and 10 (for UC).

Conclusions In patients with no risk factors, the probability of IBD flare or onset during IL-17i treatment is negligible and additional IBD screening procedures are not indicated. In contrast, the patients with psoriasis who have hidradenitis suppurativa or first-degree family history of IBD as risk factors should be monitored for signs and symptoms of CD and UC during IL-17i therapy.

Competing Interest Statement

R.G. has received speaker's honoraria from Mallinckrodt, Janssen, AbbVie, Novartis and LEO Pharma; is on advisory boards for Mallinckrodt, Janssen, Amgen, AbbVie, Eli Lilly, Sanofi, Novartis and LEO Pharma; and is an investigator in clinical trials for Janssen, Celgene, AbbVie and LEO Pharma. N.G. and M.P. have no conflicts of interest to declare.

Funding Statement

No external funding was received.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Funding sources: None

  • Conflicts of interest: R.G. has received speaker’s honoraria from Mallinckrodt, Janssen, AbbVie, Novartis and LEO Pharma; is on advisory boards for Mallinckrodt, Janssen, Amgen, AbbVie, Eli Lilly, Sanofi, Novartis and LEO Pharma; and is an investigator in clinical trials for Janssen, Celgene, AbbVie and LEO Pharma. N.G. and M.P. have no conflicts of interest to declare.

Data Availability

Data used in this study is available in the supplementary materials.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted November 19, 2019.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Risk of Inflammatory Bowel Disease in Psoriasis Patients Treated with Anti-Interleukin-17 Agents: A Bayesian Metaanalysis
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Risk of Inflammatory Bowel Disease in Psoriasis Patients Treated with Anti-Interleukin-17 Agents: A Bayesian Metaanalysis
N. Gill, M. Pietrosanu, R. Gniadecki
medRxiv 19012179; doi: https://doi.org/10.1101/19012179
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Risk of Inflammatory Bowel Disease in Psoriasis Patients Treated with Anti-Interleukin-17 Agents: A Bayesian Metaanalysis
N. Gill, M. Pietrosanu, R. Gniadecki
medRxiv 19012179; doi: https://doi.org/10.1101/19012179

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Dermatology
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (44)
  • Cardiovascular Medicine (409)
  • Dentistry and Oral Medicine (68)
  • Dermatology (47)
  • Emergency Medicine (141)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4818)
  • Forensic Medicine (3)
  • Gastroenterology (177)
  • Genetic and Genomic Medicine (671)
  • Geriatric Medicine (70)
  • Health Economics (188)
  • Health Informatics (621)
  • Health Policy (314)
  • Health Systems and Quality Improvement (200)
  • Hematology (85)
  • HIV/AIDS (155)
  • Infectious Diseases (except HIV/AIDS) (5287)
  • Intensive Care and Critical Care Medicine (327)
  • Medical Education (91)
  • Medical Ethics (24)
  • Nephrology (73)
  • Neurology (677)
  • Nursing (41)
  • Nutrition (112)
  • Obstetrics and Gynecology (126)
  • Occupational and Environmental Health (203)
  • Oncology (439)
  • Ophthalmology (138)
  • Orthopedics (36)
  • Otolaryngology (89)
  • Pain Medicine (35)
  • Palliative Medicine (15)
  • Pathology (128)
  • Pediatrics (193)
  • Pharmacology and Therapeutics (129)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (771)
  • Public and Global Health (1800)
  • Radiology and Imaging (322)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (61)
  • Surgery (100)
  • Toxicology (23)
  • Transplantation (28)
  • Urology (37)